Joaquin Duato, J&J CEO (David Zorrakino/Europa Press via Getty Images)
November 19, 2024 10:54 AM EST
R&D

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Max Gelman

Senior Editor

John­son & John­son and Pro­tag­o­nist Ther­a­peu­tics an­nounced two Phase 3 suc­cess­es for their oral IL-23 drug, show­cas­ing the first re­sults out of an ex­pan­sive piv­otal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

In­cyte’s bet on Escient hits a snag as safe­ty is­sues ham­per Phase 2 chron­ic hives tri­al

Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times